A Prospective Study on Computer-Aided Drug Design and Drug Discovery
Keywords:
Computer-Aided Drug Design (CADD), Machine Learning and Artificial Intelligence (Ai), drug discovery, Chemoinformatics, molecular modeling, molecular docking, target identificationAbstract
Computer-Aided Drug Design (CADD), which bridges the fields of biology and technology, is a revolutionary force in the ever-changing
field of drug development.The historical development of CADD, its classification into structure-based and ligand-based approaches, and its criticalfunction in streamlining and accelerating drug discovery are all covered in this study. As CADD develops, protecting data privacy and integrating avariety of biological data become critical.There are still issues that need strong ethical frameworks and algorithm optimisation.CADD's predictivepower is increased by combining machine learning and artificial intelligence, yet scalability issues and ethical issues still exist. Platforms like Open-Source Malaria serve as examples of worldwide initiatives and collaborative efforts that highlight the democratisation of medication research.Although there are ethical conundrums and accessibility issues to be resolved, the intersection of CADD and personalised medicine providescustomised therapeutic treatments. Green chemistry, immersive technology, and quantum computing are examples of emerging technologies thathave the potential to completely change CADD in the future. Rapid developments in CADD's trajectory foreshadow difficulties in guaranteeingaccuracy, mitigating AI biases, and integrating sustainability indicators.In order to create a healthier, more promising future for drug development,this paper's conclusion emphasises the need of taking proactive steps in traversing the ethical, technical, and pedagogical boundaries of CADD
References
Johnson,A.M.;Smith,B.C.Historicalperspectivesindrugdiscovery:Theadventofcomputationaltools.J. Drug Discov.1995,12,5–15.
Patel,Y.;Chalmers,D.K.Modelingdrug-receptorinteractions:Advancesandchallenges.J.Med.Chem.2003,46,2543–2554.
Green, P.L.; Edwards, P.H. Structural biology and computational chemistry:A symbiotic relationship.Chem.Rev.2010, 110, 5678–5698.
Walker,N.T.;Williams,J.P.Zanamivir:Themakingofadrug.Nat.Biotechnol.1997,15,232–235.
Martinez,A.Computationalstrategiesindrugdesign.DrugDiscov.Today2006,11,149–155.
CCBY4.0Deed/Attribution4.0International/CreativeCommons(n.d.).Availableonline:https://creativecommons.org/licenses/ by/4.0/(accessed on 10 November 2023).
Lu,W.;Zhang,R.;Jiang,H.;Zhang,H.;Luo,C.Computer-Aideddrugdesigninepigenetics.Front.Chem. 2018b,6,57.[CrossRef] [PubMed]
Kapoor,L.;Oprea,T.I.Fromempiricaltorationaldrugdiscovery:TheimportanceofCADD.DrugDes.Rev.2018,15,345–356.
Fu,C.;Xiang,M.A.;Chen,S.;Dong,G.;Liu,Z.;Chen,C.;Liang,J.;Cao,Y.;Zhang,M.;Liu,Q.Moleculardrugsimulation and experimental validation of the CD36 receptor competitively binding to Long-Chain fatty acids by 7-Ketocholesteryl-9-carboxynonanoate.ACS Omega 2023, 8, 28277–28289. [CrossRef]
Schaduangrat,N.;Lampa,S.;Simeon,S.;Gleeson,M.P.;Spjuth,O.;Nantasenamat,C.Towardsreproduciblecomputationaldrug discovery. J. Cheminform. 2020, 12, 9. [CrossRef]
Thompson,M.A.TechniquesinComputer-AidedDrugDesign.BioorganicMed.Chem.2004,12,3101–3110.
Lipinski,C.A.;Lombardo,F.;Dominy,B.W.;Feeney,P.J.Experimentalandcomputationalapproachestoestimatesolubilityand permeabilityindrugdiscoveryanddevelopmentsettings. Adv. DrugDeliv. Rev. 1997,23,3–25. [CrossRef]
ERC. Computational Biology: Spotlight on ERC projects. Available online: https://erc.europa.eu/projects-statistics/sciencestories/computational-biology-spotlight-erc-projects(accessedon27November2023).
Leach,A.R.;Gillet,V.J.Molecularmodeling:Principlesandapplications.J.Chem.Inf.Model. 2007,47,5–27.
Jumper, J.;Evans,R.;Pritzel,A.;Green,T.;Figurnov,M.;Ronneberger,O.;Tunyasuvunakool,K.;Bates,R.;Žídek,A.;Potapenko, A.; et al. Highly accurate protein structure prediction with AlphaFold. Nature2021, 596, 583–589. [CrossRef] [PubMed]
Yang, J.; Anishchenko, I.; Park, H.; Peng, Z.; Ovchinnikov, S.; Baker, D. Improved protein structure prediction using predicted interresidueorientations.Proc.Natl.Acad.Sci.USA2020,117,1496–1503.[CrossRef][PubMed]
Du, Z.; Su, H.; Wang, W.; Ye, L.; Wei, H.; Peng, Z.; Anishchenko, I.; Baker, D.; Yang, J. The trRosetta server for fast and accurate proteinstructureprediction.Nat.Protoc.2021,16,5634–5651.[CrossRef][PubMed]
Kim,D.E.;Chivian,D.;Baker,D.ProteinstructurepredictionandanalysisusingtheRobettaserver.NucleicAcidsRes.2004,32, W526–W531.[CrossRef][PubMed]
Baek,M.;DiMaio,F.;Anishchenko,I.;Dauparas,J.;Ovchinnikov,S.;Lee,G.R.;Wang,J.;Cong,Q.;Kinch,L.N.;Schaeffer,R.D.; etal.Accuratepredictionofproteinstructuresandinteractionsusingathree-trackneuralnetwork.Science2021,373,871–876. [CrossRef]
Lin, Z.; Akin, H.; Rao, R.; Hie, B.; Zhu, Z.; Lu, W.; Smetanin, N.; Verkuil, R.; Kabeli, O.; Shmueli, Y.; et al. Language models of proteinsequencesatthescaleofevolutionenableaccuratestructureprediction.bioRxiv2022,2020,500902.[CrossRef]
Wu, R.; Ding, F.; Wang, R.; Shen, R.; Zhang, X.; Luo, S.; Su, C.; Wu, Z.; Xie, Q.; Berger, B.; et al. High-resolution de novo structureprediction from primary sequence. bioRxiv 2022. [CrossRef]
Niazi,S.K.;Mariam,Z.ReinventingTherapeuticProteins:Miningatreasureofnewtherapies.Biologics2023,3,72–94.[CrossRef]
Berendsen, H.J.C.; Van Der Spoel, D.; Van Drunen, R. GROMACS: A message-passing parallel molecular dynamics implementation.Comput. Phys. Commun. 1995,91,43–56. [CrossRef]
Harvey, M.;Giupponi,G.;DeFabritiis,G.ACEMD:AcceleratingBiomolecularDynamicsintheMicrosecondTimeScale. J.Chem. TheoryComput.2009,5,1632–1639. [CrossRef][PubMed]
Eastman, P.; Swails, J.; Chodera, J.D.; McGibbon, R.T.; Zhao, Y.; Beauchamp, K.A.; Wang, L.; Simmonett, A.C.; Harrigan, M.P.; Stern, C.; et al. OpenMM 7: Rapid development of high performance algorithms for molecular dynamics.PLoS Comput. Biol. 2017, 13, e1005659. [CrossRef] [PubMed]
Adcock,S.A.;McCammon,J.A.Moleculardynamics:Surveyofmethodsforsimulatingtheactivityofproteins.Chem.Rev.2006, 106,1589–1615.[CrossRef][PubMed]
Morris,G.M.;Lim-Wilby,M.Moleculardocking.MethodsMol.Biol.2008,443,365–382.[PubMed]
Trott,O.;Olson,A.J.AutoDockVina:Improvingthespeedandaccuracyofdockingwithanewscoringfunction,efficient optimization,andmultithreading. J.Comput. Chem. 2010,31,455–461. [CrossRef][PubMed]
Morris,G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4:Automateddockingwithselectivereceptorflexibility. J.Comput.Chem.2009,30,2785–2791. [CrossRef][PubMed]
Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Shenkin, P.S. Glide:A new approach for rapid,accuratedockingandscoring. 1. Methodandassessmentofdockingaccuracy. J.Med.Chem.2004,47,1739–1749. [CrossRef]
Ewing, T.J.A.; Makino, S.; Skillman, A.G.; Kuntz, I.D. DOCK 4.0:Search strategies for automated molecular docking of flexible moleculedatabases. J.Comput.AidedMol.Des.2001,15,411–428. [CrossRef]
Venkatachalam, C.M.; Jiang, X.; Oldfield, T.; Waldman, M. LigandFit:A novel method for the shape-directed rapid docking of ligandstoproteinactivesites. J.Mol.Graph.Model.2003,21,289–307. [CrossRef]
Bitencourt-Ferreira,G.;DeAzevedo,W.F.DockingwithSwissDock.MethodsMol.Biol.2019,2053,189–202.[CrossRef][PubMed]
Willett,P.Virtualscreeningusingmoleculardocking.DrugDiscov.TodayTechnol.2006,3,229–234.
Karatzas, E.; Zamora, J.E.; Athanasiadis, E.; Dellis, D.; Cournia, Z.; Spyrou, G.M. ChemBioServer 2.0: An advanced web server forfiltering,clusteringandnetworkingofchemicalcompoundsfacilitatingbothdrugdiscoveryandrepurposing.Bioinformatics 2020, 36, 2602–2604. [CrossRef] [PubMed]
Pinzi,L.;Rastelli,G.Moleculardocking:Shiftingparadigmsindrugdiscovery.Int.J.Mol.Sci.2019,20,4331.[CrossRef] [PubMed]
Sahoo,R.N.;Pattanaik,S.;Pattnaik,G.;Mallick,S.;Mohapatra,R.ReviewontheuseofMolecularDockingastheFirstLineTool inDrugDiscoveryandDevelopment. IndianJ.Pharm. Sci. 2022,84,1334–1337. [CrossRef]
Hansch,C.;Leo,A.ExploringQSAR:Hydrophobic,Electronic,andStericConstants;ACSProfessionalReferenceBook:Washington, DC,USA,1995.
Niazi, S.K.; Mariam, Z. Recent Advances in Machine-Learning-Based Chemoinformatics: A Comprehensive Review. Int. J.Mol. Sci.2023, 24, 11488. [CrossRef] [PubMed]
Luo,M.;Wang,X.S.;Tropsha,A.ComparativeAnalysisofQSAR-basedvs.ChemicalSimilarityBasedPredictorsofGPCRs Binding Affinity. Mol. Inform. 2016, 35, 36–41. [CrossRef]
Raj, N.; Jain, S.K. 3d QSAR studies in conjunction with k-nearest neighbor molecular field analysis (k-NN-MFA) on a series of substituted 2-phenyl-benzimidazole derivatives as an anti allergic agents.Dig. J.Nanomater. Biostructures2011, 6, 1811–1821.
Nigsch,F.;Bender,A.;vanBuuren,B.;Tissen,J.;Nigsch,E.;Mitchell,J.B.Meltingpointpredictionemployingk-nearestneighbor algorithmsandgeneticparameteroptimization. J.Chem.Inf.Model.2006,46,2412–2422. [CrossRef]
Güner,O.F.Pharmacophoreperception,development,anduseindrugdesign.J.Med.Chem.2002,45,5–12.
Zhang, Y.; Yang, S.; Jiao, Y.; Liu, H.; Yuan, H.; Lü, S.; Ran, T.; Yao, S.; Ke, Z.; Xu, J.; et al. An integrated virtual screening approach forVEGFR-2inhibitors. J.Chem. Inf. Model. 2013,53,3163–3177. [CrossRef][PubMed]
Fidom, K.; Ísberg, V.; Hauser, A.S.; Mordalski, S.; Lehto, T.; Bojarski, A.J.; Gloriam, D.E. A new crystal structure fragment-based pharmacophoremethodforGprotein-coupledreceptors. Methods2015,71,104–112. [CrossRef][PubMed]
Munk, C.; Harpsøe, K.; Hauser, A.S.; Isberg, V.; Gloriam, D.E. Integrating structural and mutagenesis data to elucidate GPCRligand binding. Curr. Opin. Pharmacol. 2016, 30, 51–58. [CrossRef] [PubMed]
Ekins,S.;Williams,A.J.Insilicopharmacokinetics:ADMEindrugdiscovery.DrugDiscov.World2007,8,17–24.
Schneider, G.; Fechner, U. Computer-based de novo design of drug-like molecules.Nat.Rev.Drug Discov.2005, 4, 649–663. [CrossRef] [PubMed]
Zhang,L.;Tan,J.AIanditsroleindrugdiscovery.J.DrugDiscov.Des.2019,5,1–10.
Bishop,C.M.PatternRecognitionandMachineLearning;Springer:Berlin/Heidelberg,Germany,2006.
Goh,G.B.;Hodas,N.O.;Vishnu,A.Deeplearningforcomputationalchemistry.J.Comput.Chem.2017,38,1291–1307.[CrossRef]
Vilar, S.; Uriarte, E.; Santana, L.; Lorberbaum, T.; Hripcsak, G. Predicting drug-drug interactions through drug structural similaritiesandinteractionnetworksincorporatingpharmacokineticsandpharmacodynamicsknowledge. J.Cheminformatics 2016, 8, 12.
Aliper, A.; Plis, S.; Artemov, A.; Ulloa, A.; Mamoshina, P.; Zhavoronkov, A. Deep learning applications for predicting pharmacologicalpropertiesofdrugsanddrugrepurposingusingtranscriptomicdata.Mol.Pharm.2016,13,2524–2530.[CrossRef]
Kadurin,A.;Aliper,A.;Kazennov,A.;Mamoshina,P.;Vanhaelen,Q.;Khrabrov,K.;Zhavoronkov,A.Thecornucopiaofmeaningful leads: Applyingdeepadversarialautoencodersfornewmoleculedevelopmentinoncology.Oncotarget2017,8,10883–10890. [CrossRef]
Mayr, A.;Klambauer,G.;Unterthiner,T.;Hochreiter,S.DeepTox:Toxicitypredictionusingdeeplearning.Front.Environ.Sci. 2016,3,80.[CrossRef]
Chen,H.;Engkvist,O.;Wang,Y.;Olivecrona,M.;Blaschke,T.Theriseofdeeplearningindrugdiscovery.DrugDiscov.Today 2018,23,1241–1250.[CrossRef][PubMed]
Jorgensen,W.L.Themanyrolesofcomputationindrugdiscovery.Science2004,303,1813–1818.[CrossRef][PubMed]
Warren,G.L.;Andrews,C.W.;Capelli,A.M.;Clarke,B.;LaLonde,J.;Lambert,M.H.;Murray,C.W.Acriticalassessmentofdocking programsandscoringfunctions. J.Med.Chem.2006,49,5912–5931. [CrossRef][PubMed]
Aleksandrova, A. Machine-Learning Scoring Functions to Improve Structure-Based Binding Affinity Prediction and Virtual Screening. 2016. Availableonline: https://www.academia.edu/28830051/Machine_learning_scoring_functions_to_improve_structure_based_binding_affinity_p rediction_and_virtual_screening(accessed on 10 November 2023).
Fujimoto, K.; Minami, S.; Yanai, T. Machine-Learning- and Knowledge-Based scoring functions incorporating ligand and proteinfingerprints.ACS Omega 2022, 7, 19030–19039. [CrossRef] [PubMed]
Guedes, I.A.; Barreto, A.; Marinho, D.; Krempser, E.; Kuenemann, M.A.; Spérandio, O.; Dardenne, L.E.; Miteva, M.A. New machinelearningandphysics-basedscoringfunctionsfordrugdiscovery. Sci. Rep. 2021,11,3198. [CrossRef]
Walters,W.P.;Murcko,M.A.Predictionof‘drug-likeness’.Adv. DrugDeliv. Rev.2002,54,255–271.[CrossRef]
Kitchen, D.B.; Decornez, H.; Furr, J.R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: Methods and applications. Nat.Rev.DrugDiscov.2004,3,935–949. [CrossRef]
Dror, R.O.; Dirks, R.M.; Grossman, J.P.; Xu, H.; Shaw, D.E. Biomolecular simulation: A computational microscope for molecular biology. Annu.Rev.Biophys.2012,41,429–452. [CrossRef]
Teague,S.J.Implicationsofproteinflexibilityfordrugdiscovery.Nat.Rev.DrugDiscov.2003,2,527–541.[CrossRef]
Ching,T.;Himmelstein,D.S.;Beaulieu-Jones,B.K.;Kalinin,A.A.;Do,B.T.;Way,G.P.;Greene,C.S.Opportunitiesandobstaclesfordeep learning in biology and medicine.J. R. Soc.Interface 2018, 15, 20170387.[CrossRef] [PubMed]
Bajorath,J.Integrationofvirtualandhigh-throughputscreening.Nat.Rev.DrugDiscov.2012,1,882–894.[CrossRef][PubMed]
Shoichet,B.K.Virtualscreeningofchemicallibraries.Nature2004,432,862–865.[CrossRef][PubMed]
Macarron,R.;Banks,M.N.;Bojanic,D.;Burns,D.J.;Cirovic,D.A.;Garyantes,T.;Hertzberg,R.P.Impactofhigh-throughput screeninginbiomedicalresearch.Nat.Rev.DrugDiscov.2011,10,188–195.[CrossRef][PubMed]
Zhang,J.H.;Chung,T.D.;Oldenburg,K.R.Asimplestatisticalparameterforuseinevaluationandvalidationofhighthroughput screeningassays. J.Biomol. Screen. 1999,4,67–73. [CrossRef][PubMed]
Pound, P.;Bracken,M.B.Isanimalresearchsufficientlyevidence-basedtobeacornerstoneofbiomedicalresearch?BMJ 2014, 348, g3387.[CrossRef][PubMed]
Blundell,T.L.Proteincrystallographyanddrugdiscovery:Recollectionsofknowledgeexchangebetweenacademiaandindustry. IUCrJ2017,4,308–321. [CrossRef]
Sterling,T.;Irwin,J.J.ZINC15—Liganddiscoveryforeveryone.J.Chem.Inf.Model.2015,55,2324–2337.[CrossRef]
Schneider,G.Automatingdrugdiscovery.Nat.Rev.DrugDiscov.2018,17,97–113.[CrossRef]
Vamathevan, J.; Clark, D.; Czodrowski, P.; Dunham, I.; Ferran, E.; Lee, G.; Puhl, A.C. Applications of machine learning in drugdiscoveryanddevelopment. Nat.Rev.DrugDiscov.2019,18,463–477. [CrossRef]
Qureshi, R.; Irfan, M.; Gondal, T.M.; Khan, S.; Wu, J.; Hadi, M.U.; Heymach, J.; Le, X.; Yan, H.; Alam, T. AI in drug discovery andits clinical relevance. Heliyon2023, 9, e17575. [CrossRef] [PubMed]
Zhang, L.; Tan, J.; Han, D.; Zhu, H. From machine learning to deep learning: Progress in machine intelligence for rational drug discovery.DrugDiscov.Today2017,22,1680–1685.[CrossRef][PubMed]
Le, W.T.; Maleki, F.; Romero, F.P.; Forghani, R.; Kadoury, S. Overview of Machine Learning: Part 2: Deep Learning for Medical ImageAnalysis. NeuroimagingClin. N.Am. 2020,30,417–431. [CrossRef][PubMed]
Walters,W.P.;Murcko,M.AssessingtheimpactofgenerativeAIonmedicinalchemistry.Nat.Biotechnol.2020,38,143–145. [CrossRef][PubMed]
Topol,E.J.High-performancemedicine:Theconvergenceofhumanandartificialintelligence.Nat.Med.2019,25,44–56. [CrossRef] [PubMed]
Hasin,Y.;Seldin,M.;Lusis,A.Multi-omicsapproachestodisease.GenomeBiol.2017,18,83.[CrossRef][PubMed]
Nicholson,J.K.;Lindon,J.C.Systemsbiology:Metabonomics.Nature2008,455,1054–1056. [CrossRef]
Zhang,W.;Chien,J.;Yong,J.;Kuang,R.Network-basedmachinelearningandgraphtheoryalgorithmsforprecisiononcology. NPJPrecis.Oncol.2017,1,25.[CrossRef]
Subramanian,I.;Verma,S.;Kumar,S.;Jere,A.;Anamika,K.Multi-omicsDataIntegration,Interpretation,andItsApplication. Bioinform.Biol.Insights2020,14,1177932219899051.[CrossRef]
Kim,M.S.;Pinto,S.M.;Getnet,D.;Nirujogi,R.S.;Manda,S.S.;Chaerkady,R.;Prasad,T.S.K.Adraftmapofthehumanproteome. Nature2014,509,575–581. [CrossRef]
Wishart, D.S. Emerging applications of metabolomics in drug discovery and precision medicine. Nat. Rev. Drug Discov. 2016, 15,473–484. [CrossRef] [PubMed]
Barabási,A.L.;Gulbahce,N.;Loscalzo,J.Networkmedicine:Anetwork-basedapproachtohumandisease.Nat.Rev.Genet.2011, 12,56–68.[CrossRef][PubMed]
Williams, A.J.; Harland, L.; Groth, P.; Pettifer, S.; Chichester, C.; Willighagen, E.L.; Goble, C. Open PHACTS: Semantic interoperabilityfordrugdiscovery.DrugDiscov.Today2012,17,1188–1198.[CrossRef][PubMed]
Cournia, Z.; Allen, B.; Sherman, W. Relative binding free energy calculations in drug discovery: Recent advances and practicalconsiderations.J. Chem. Inf. Model. 2017, 57, 2911–2937. [CrossRef] [PubMed]
Gayathiri, E.; Prakash, P.; Kumaravel, P.; Jayaprakash, J.; Ragunathan, M.G.; Sankar, S.; Pandiaraj, S.; Thirumalaivasan, N.; Thiruvengadam,M.;Govindasamy,R.Computationalapproachesformodelingandstructuraldesignofbiologicalsystems: Acomprehensivereview. Prog. Biophys. Mol. Biol. 2023,185,17–32. [CrossRef][PubMed]
Sastry,G.M.;Adzhigirey,M.;Day,T.;Annabhimoju,R.;Sherman,W.Proteinandligandpreparation: Parameters,protocols,and influenceonvirtualscreeningenrichments. J.Comput.AidedMol.Des.2013,27,221–234. [CrossRef]
Meng, X.Y.; Zhang, H.X.; Mezei, M.; Cui, M. Molecular docking: A powerful approach for structure-based drug discovery. Curr. Comput.AidedDrugDes.2011,7,146–157. [CrossRef]
Mascalzoni,D.;Dove,E.S.;Rubinstein,Y.;Dawkins,H.J.;Kole,A.;McCormack,P.;Woods,S.InternationalCharterofprinciplesfor sharing biospecimens and data.Eur. J. Hum. Genet. 2014, 23, 721–728.[CrossRef]
Bassani,D.;Moro,S.Past,Present,andFuturePerspectivesonComputer-AidedDrugDesignMethodologies.Molecules2023,28, 3906.[CrossRef]
Wlodawer, A.;Vondrasek,J.InhibitorsofHIV-1protease: Amajorsuccessofstructure-assisteddrugdesign.Annu. Rev. Biophys. Biomol. Struct. 1998,27,249–284. [CrossRef]
von Itzstein, M. The war against influenza: Discovery and development of sialidase inhibitors. Nat. Rev. DrugDiscov. 2007, 6, 967–974. [CrossRef] [PubMed]
Deininger,M.W.N.;Druker,B.J.Specifictargetedtherapyofchronicmyelogenousleukemiawithimatinib.Pharmacol.Rev.2003, 55,401–423.[CrossRef][PubMed]
Harper,S.;McCauley,J.A.;Rudd,M.T.RecentadvancesinthediscoveryofsmallmoleculeinhibitorsofhepatitisCvirus.Annu. Rev. Pharmacol. Toxicol. 2014, 54, 317–338.
Ghosh, A.K.; Brindisi, M.; Tang, J. Developing β-secretase inhibitors for treatment of Alzheimer’s disease. J. Neurochem. 2012, 120, 71–83. [CrossRef] [PubMed]
Mintun, M.A.; Lo, A.; Evans, C.; Wessels, A.M.; Ardayfio, P.; Andersen, S.W.; Shcherbinin, S.; Sparks, J.; Sims, J.R.; Brys´, M.; et al. DonanemabinearlyAlzheimer’sdisease. N.Engl. J.Med. 2021,384,1691–1704. [CrossRef][PubMed]
Doody,R.R.S.;Thomas,R.R.G.R.;Farlow,M.R.;Iwatsubo,T.;Vellas,B.;Joffe,S.;Kieburtz,K.;Raman,R.;Sun,X.;Aisen,P.S.; etal. Phase3trialsofSolanezumabforMild-to-ModerateAlzheimer’sDisease. N.Engl.J.Med.2014,370,311–321. [CrossRef] [PubMed]
Rani, I.; Kalsi, A.; Kaur, G.; Sharma, P.; Gupta, S.; Gautam, R.K.; Chopra, H.; Bibi, S.; Ahmad, S.U.; Singh, I.; et al. Modern drug discovery applications for the identification of novel candidates for COVID-19 infections.Ann. Med. Surg.2022, 80, 104125. [CrossRef]
Amir, S.; Arathi, A.; Reshma, S.; Mohanan, P.V. Microfluidic devices for the detection of disease-specific proteins and other macromolecules,diseasemodellinganddrugdevelopment: Areview. Int.J.Biol.Macromol.2023,235,123784. [CrossRef]
Cao, Y.; Romero, J.; Olson, J.P.; Degroote, M.; Johnson, P.D.; Kieferová, M.; Aspuru-Guzik, A. Quantum chemistry in the age of quantumcomputing. Chem.Rev.2019,119,10856–10915. [CrossRef]
O’Connor, M.; Deeks, H.M.; Dawn, E.; Metatla, O.; Roudaut, A.; Sutton, M.; Glowacki, D.R. Sampling molecular conformations anddynamicsinamulti-uservirtualrealityframework. Sci. Adv. 2018,4,eaat2731. [CrossRef]
Ryan, D.K.; Maclean, R.H.; Balston, A.; Scourfield, A.; Shah, A.D.; Ross, J. Artificial intelligence and machine learning for clinical pharmacology. Br. J.Clin. Pharmacol. 2023. [CrossRef] [PubMed]
Collins,F.S.;Varmus,H.Anewinitiativeonprecisionmedicine.N.Engl.J.Med.2015,372,793–795.[CrossRef][PubMed]
Kanza, S.; Frey, J.G. A new wave of innovation in Semantic web tools for drug discovery.Expert Opin.Drug Discov.2019, 14, 433–444. [CrossRef] [PubMed]
Anastas,P.;Eghbali,N.Greenchemistry:Principlesandpractice.Chem.Soc.Rev.2010,39,301–312.[CrossRef][PubMed]
Woelfle,M.;Olliaro,P.;Todd,M.H.Openscienceisaresearchaccelerator.Nat.Chem.2011,3,745–748.[CrossRef][PubMed]
Morgera,E.;Tsioumani,E.;Buck,M.UnravelingtheNagoyaProtocol:AcommentaryontheNagoyaProtocolonAccessandBenefit- SharingtotheConventiononBiologicalDiversity;Brill: Leiden,TheNetherlands,2014.
Bhardwaj, A.; Scaria, V.; Raghava, G.P.; Lynn, A.M.; Chandra, N.; Banerjee, S.; Open Source Drug Discovery Consortium. Open source drug discovery—A new paradigm of collaborative research in tuberculosis drug development.Tuberculosis 2011, 91, 479–486. [CrossRef] [PubMed]
Ranard,B.L.;Ha,Y.P.;Meisel,Z.F.;Asch,D.A.;Hill,S.S.;Becker,L.B.;Merchant,R.M.Crowdsourcing—Harnessingthemassesto advancehealthandmedicine,asystematicreview. J.Gen.Intern.Med.2014,29,187–203. [CrossRef]
Warr,W.A.Scientificworkflowsystems:PipelinePilotandKNIME.J.Comput.AidedMol.Des.2012,26,801–804.[CrossRef]
McKiernan,E.C.;Bourne,P.E.;Brown,C.T.;Buck,S.;Kenall,A.;Lin,J.;Spies,J.R.Howopensciencehelpsresearcherssucceed. eLife2016,5,e16800.[CrossRef]
Mons, B.; Neylon, C.; Velterop, J.; Dumontier, M.; da Silva Santos, L.O.B.; Wilkinson, M.D. Cloudy, increasingly FAIR: Revisiting the FAIR Data guiding principles for the European Open Science Cloud. Inf. Serv. Use2017, 37, 49–56. [CrossRef]
Brownsword,R.;Goodwin,M.LawandtheTechnologiesoftheTwenty-FirstCentury;CambridgeUniversityPress:Cambridge,UK, 2012.
Voigt,P.;VondemBussche,A.TheEUGeneralDataProtectionRegulation(GDPR);SpringerInternationalPublishing: Berlin/Heidelberg, Germany, 2017.
Torrance,A.W.; Tomlinson,B. Patentsand theRegress ofUseful Arts.ColumbiaSci.Technol.LawRev.2019,10, 130–168.
Mitchell,M.; Wu,S.; Zaldivar,A.; Barnes,P.; Vasserman,L.; Hutchinson,B.; Gebru,T.Modelcardsformodelreporting.In ProceedingsoftheConferenceonFairness2019,Accountability,andTransparency,Atlanta,GA,USA,29–31January2019; pp.220–229.
Baker,M.1500scientistsliftthelidonreproducibility.Nat.News 2016,533,452.[CrossRef][PubMed]
Tannenbaum, J.; Bennett, B.T. Russell and Burch′s 3Rs then and now:The need for clarity in definition and purpose.J. Am. Assoc. Lab. Anim. Sci. 2015, 54, 120–132. [PubMed]
Eichler,H.G.;Pignatti,F.;Flamion,B.;Leufkens,H.;Breckenridge,A.Balancingearlymarketaccesstonewdrugswiththeneedforbenefit/risk data:Amountingdilemma.Nat.Rev.Drug Discov.2008,7,818–826.[CrossRef][PubMed]
Hughes,J.P.;Rees,S.;Kalindjian,S.B.;Philpott,K.L.Principlesofearlydrugdiscovery.Br.J.Pharmacol.2011,162,1239–1249. [CrossRef][PubMed]
Hulsen,T.Literatureanalysisofartificialintelligenceinbiomedicine.Ann.Transl.Med.2022,10,1284.[CrossRef][PubMed]
Wilkinson, M.D.; Dumontier, M.; Aalbersberg, I.J.; Appleton, G.; Axton, M.; Baak, A.; Bouwman, J. The FAIR Guiding Principles forscientificdatamanagementandstewardship. Sci. Data2016,3,160018. [CrossRef]
Brankovic´, M. Green chemical analysis: Main principles and current efforts towards greener analytical methodologies.Anal. Methods2023,15,6631–6642. [CrossRef]
Rahwan,I.;Cebrian,M.;Obradovich,N.;Bongard,J.;Bonnefon,J.F.;Breazeal,C.;Jennings,N.R.Machinebehaviour.Nature2019, 568,477–486. [CrossRef]
Karplus,M.;Petsko,G.A.Moleculardynamicssimulationsinbiology. Nature1990,347,631–639. [CrossRef]
Paul, S.M.;Mytelka,D.S.;Dunwiddie,C.T.;Persinger,C.C.;Munos,B.H.;Lindborg,S.R.;Schacht,A.L.HowtoimproveR&D productivity:Thepharmaceuticalindustry′sgrandchallenge.Nat.Rev.Drug Discov.2010,9,203–214.[PubMed]
Deliorman,M.;Ali,D.S.;Qasaimeh,M.A.Next-GenerationMicrofluidicsforBiomedicalResearchandHealthcareApplications. Biomed.Eng.Comput.Biol.2023,14,11795972231214387.[CrossRef][PubMed]
Case,D.A.;Cheatham,T.E.;Darden,T.;Gohlke,H.;Luo,R.;Merz,K.M.;Woods,R.J.TheAmberbiomolecularsimulation programs. J.Comput.Chem.2005,26,1668–1688. [CrossRef][PubMed]
Breinig, M.; Klein, F.A.; Huber, W.; Boutros, M. A chemical-genetic interaction map of small molecules using high-throughput imaging in cancer cells. Mol. Syst. Biol. 2015, 11, 846. [CrossRef] [PubMed]
Tindall,M.J.;Cucurull- Sanchez,L.;Mistry,H.;Yates,J.W.T.QuantitativeSystemsPharmacologyandMachineLearning:AMatchMadeinHeavenorHell?J. Pharmacol.Exp.Ther.2023,387,92–99.[CrossRef][PubMed]
Boran,A.D.;Iyengar,R.Systemsapproachestopolypharmacologyanddrugdiscovery.Curr.Opin.DrugDiscov.Dev.2010,13, 297–309.
Kirchmair,J.;Göller,A.H.;Lang,D.;Kunze,J.;Testa,B.;Wilson,I.D.;Schneider,G. Predicting drug metabolism:Experiment and/orcomputation? Nat.Rev.DrugDiscov.2015,14,387–404. [CrossRef]
Oprea,T.I.;Gottfries,J.Chemography:Theartofnavigatinginchemicalspace.J.Comb.Chem.2001,3,157–166. [CrossRef]
Xia,S.;Chen,E.;Zhang,Y.IntegratedMolecularModelingandMachineLearningforDrugDesign.J.Chem.TheoryComput.2023, 19,7478–7495.[CrossRef]
Pirard,B.Thequestfornovelchemicalmatterandthecontributionofcomputer-aideddenovodesign.ExpertOpin.DrugDiscov. 2011,6,225–231.[CrossRef]
Ekins, S.; Puhl, A.C.; Zorn, K.M.; Lane, T.R.; Russo, D.P.; Klein, J.J.; Zahoránszky-Ko˝halmi,G. Exploiting machine learning forend-to-enddrugdiscoveryanddevelopment. Nat. Mater. 2019,18,435–441. [CrossRef][PubMed]
Lusher,S.J.;McGuire,R.;vanSchaik,R.C.;Nicholson,C.D.;deVlieg,J.Data-drivenmedicinalchemistryintheeraofbigdata. DrugDiscov.Today2011,19,859–868.[CrossRef][PubMed]
Good, A.C.; Krystek, S.R.; Mason, J.S. High-throughput and virtual screening: Core lead discovery technologies move towards integration.DrugDiscov. Today2000,5,61–69. [CrossRef][PubMed]
Andrade,E.L.;Bento,A.F.;Cavalli,J.;Oliveira,S.K.;Freitas,C.S.;Marcon,R.;Schwanke,R.C.;Siqueira,J.M.;Calixto,J.B. Nonclinicalstudiesrequiredfornewdrugdevelopment—PartI:Earlyinsilicoandinvitrostudies,newtargetdiscoveryand validation,proofofprinciplesandrobustnessofanimalstudies. Braz. J.Med. Biol. Res. 2016,49,e5644. [CrossRef][PubMed]
James,T.;Hristozov,D.DeepLearningandComputationalChemistry.MethodsMol.Biol.2022,2390,125–151.[CrossRef] [PubMed]
Wells, J.A.; McClendon, C.L. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces. Nature2007, 450, 1001–1009. [CrossRef]
Lyon,J.AIethicsinpredictivemodelingandprecisionmedicine.J.Mol.Biol.2019,431,4118–4134.
Karczewski,K.J.;Snyder, M.P.Integrative omicsfor healthand disease.Nat.Rev.Genet.2018,19, 299–310.[CrossRef]
Gierend, K.; Waltemath, D.; Ganslandt, T.; Siegel, F. Traceable Research Data Sharing in a German Medical Data Integration Center WithFAIR(Findability,Accessibility,Interoperability,andReusability)-GearedProvenanceImplementation:Proof-of-Concept Study. JMIRFormRes. 2023, 7, e50027. [CrossRef]
Shultz,M.D.Considerationsfordesigningandprioritizingcomputationaldrugdiscovery.SLASDiscov.2019,24,468–486.
Shabani, A.; Rajabi, S.; Alipanahi, N.; Ahmadi Teymourlouy, A. Key Factors to Improve Pharmaceutical Industry’s R&D Productivity: A Case Study of Iranian Pharmaceutical Holding. Med. J.IslamRepub. Iran. 2022, 36, 117. [CrossRef] [PubMed]
Sullivan,J.A.; Dumont, J.R.; Memar, S.; Skirzewski, M.; Wan, J.; Mofrad, M.H.; Ansari, H.Z.; Li, Y.; Muller, L.; Prado, V.F.; et al.New frontiers in translational research: Touchscreens, open science, and the mouse translational research accelerator platform.GenesBrainBehav. 2021,20,e12705. [CrossRef][PubMed]
Goldman,M.Theinnovativemedicinesinitiative:AEuropeanresponsetotheinnovationchallenge.Clin.Pharmacol.Ther.2012, 91,418–425.[CrossRef][PubMed]
Wang,Y.;Suzek,T.;Zhang,J.;Wang,J.;He,S.;Cheng,T.;Gindulyte,A.PubChemBioAssay:2014update.NucleicAcidsRes.2014, 42,D1075–D1082.[CrossRef][PubMed]
Chen, Y.; Elenee Argentinis, J.D. IBM Watson: How cognitive computing can be applied to big data challenges in life sciences research. Clin.Ther.2016,38,688–701. [CrossRef][PubMed]
Monge,A.;Arrault,A.;Marot,C.University–industrycollaborationindrugdiscoveryanddevelopments:Amatterofsynergies. DrugDiscov.Today2011,16,1106–1114.
Pisani, E.; AbouZahr, C. Sharing health data: Good intentions are not enough.Bull. World Health Organ.2010, 88, 462–466. [CrossRef]
Hamburg,M.A.;Collins,F.S.Thepathtopersonalizedmedicine. N.Engl.J.Med.2010,363,301–304. [CrossRef]
McCarthy, M.I.; Abecasis, G.R.; Cardon, L.R.; Goldstein, D.B.; Little, J.; Ioannidis, J.P.; Hirschhorn, J.N. Genome-wide association studiesforcomplextraits: Consensus,uncertaintyandchallenges. Nat.Rev.Genet.2008,9,356–369. [CrossRef]
Nelson,M.R.;Johnson,T.;Warren,L.;Hughes,A.R.;Chissoe,S.L.;Xu,C.F.;Waterworth,D.M.Thegeneticsofdrugefficacy: Opportunitiesandchallenges. Nat. Rev. Genet. 2016,17,197–210. [CrossRef]
Mirnezami,R.;Nicholson,J.;Darzi,A.Preparingforprecisionmedicine.N. Engl.J.Med.2012,366,489–491.[CrossRef][PubMed]
Garraway,L.A.;Lander,E.S.Lessonsfromthecancergenome.Cell2013,153,17–37.[CrossRef][PubMed]
Piwek,L.;Ellis,D.A.;Andrews,S.;Joinson,A.Theriseofconsumerhealthwearables:Promisesandbarriers.PLoS Med.2016,13,e1001953. [CrossRef] [PubMed]
Phillips,K.A.;AnnSakowski,J.;Trosman,J.;Douglas,M.P.;Liang,S.Y.;Neumann,P.Theeconomicvalueofpersonalized medicinetests: Whatweknowandwhatweneedtoknow. Genet. Med. 2014,16,251–257. [CrossRef][PubMed]
Schneider,P.;Walters,W.P.;Plowright,A.T.Rethinkingdrugdesignintheartificialintelligenceera.Nat.Rev.DrugDiscov.2016, 19,353–364.[CrossRef][PubMed]
Gómez-Bombarelli,R.;Wei,J.N.;Duvenaud,D.;Hernández-Lobato,J.M.;Sánchez-Lengeling,B.;Sheberla,D.;Aspuru-Guzik, A.Automaticchemicaldesignusingadata-drivencontinuousrepresentationofmolecules.ACSCent.Sci.2018,4,268–276.[CrossRef] [PubMed]
Wang, Y.; Yella, J.; Jegga, A.G. Transcriptomic Data Mining and Repurposing for Computational Drug Discovery. MethodsMol. Biol.2019, 1903, 73–95. [CrossRef]
Vapnik,V.TheNatureofStatisticalLearningTheory;Springer:Berlin/Heidelberg,Germany,2013.
Preuer, K.; Renz, P.; Unterthiner, T.; Hochreiter, S.; Klambauer, G. Fréchet ChemNet Distance:A Metric for Generative Models forMolecules in Drug Discovery.J. Chem. Inf. Model. 2018, 58, 1736–1741.[CrossRef]
Feng, Y.; Zhang, L.; Yi, Z. Breast cancer cell nuclei classification in histopathology images using deep neural networks.Int.J. Comput.Assist.Radiol.Surg.2018,13,179–191. [CrossRef]
